Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RASAGILINE | 1MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 472 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 441 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-03-11 | 2017-03-28 | 469 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2017-06-27 | 2017-11-13 | 14011 |
| APO-RASAGILINE | 0.5MG | TABLET | Resolved | 2019-06-12 | 2019-08-30 | 86327 |
| APO-REPAGLINIDE | 2.0MG | TABLET | Resolved | 2017-03-11 | 2018-09-11 | 481 |
| APO-REPAGLINIDE | 0.5MG | TABLET | Resolved | 2017-03-11 | 2018-09-11 | 475 |
| APO-REPAGLINIDE | 1.0MG | TABLET | Resolved | 2017-03-11 | 2018-09-11 | 478 |
| APO-RILUZOLE | 50MG | TABLET | Actual shortage | 2024-06-07 | 2024-12-19 | 229974 |
| APO-RILUZOLE | 50MG | TABLET | Resolved | 2019-07-12 | 2019-09-16 | 89170 |
| APO-RILUZOLE | 50MG | TABLET | Resolved | 2020-01-15 | 2022-09-23 | 103385 |
| APO-RILUZOLE | 50MG | TABLET | Resolved | 2017-08-30 | 2018-02-28 | 20648 |
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2017-03-11 | 2017-05-02 | 598 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2017-10-23 | 2017-11-15 | 26643 |
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2018-08-21 | 2018-10-19 | 58626 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2017-03-11 | 2017-03-15 | 484 |
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2018-10-19 | 2018-12-21 | 64981 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2022-02-04 | 2022-03-07 | 154197 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2018-05-02 | 2018-07-03 | 47969 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2021-09-10 | 2022-03-04 | 145468 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 9MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110977 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |